3 years ago

NeoPhore Secures £6M Extension to Series B, Bringing Total to £21.5M

  • NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised £6M in an extension to its Series B funding, now totaling £21.5M

  • The investors included CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health Fund and Astellas Venture Management

  • NeoPhore intends to use the funds to progress its expanding pipeline of drugs to the start of IND-enabling studies in 2024.

      • ProblemHealthcare

      "making cancer treatments more effective by exploiting genetic mutations in tumours"

      Solution

      "developing small molecule therapies that stimulate the immune system to fight cancer"

      Covered on